[
  {"id":"B02-20160301-001","en":"ANDS (Abbreviated New Drug Submission)","fr":"ANDS (Présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-031","en":"EU NDS (Extraordinary Use New Drug Submission)","fr":"EU NDS (Présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-032","en":"EUSNDS (Extraordinary Use Supplement to a New Drug Submission)","fr":"EUSNDS (Supplément à une présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-038","en":"Level 3 - Notice of Change (Post-Notice of Compliance Changes - Level III)","fr":"Level 3 - Notice of Change (Changements survenus après l'avis de conformité - Niveau III)"},
  {"id":"B02-20160301-041","en":"MPANDS","fr":"MPANDS"},
  {"id":"B02-20160301-046","en":"MPNC (Pre-NC Meeting)","fr":"MPNC (Réunion préalable - PM)"},
  {"id":"B02-20160301-047","en":"MPNDS (Pre-NDS Meeting)","fr":"MPNDS (Réunion préalable – PDN)"},
  {"id":"B02-20160301-048","en":"MPSANDS","fr":"MPSANDS"},
  {"id":"B02-20160301-049","en":"MPSNDS (Pre-SNDS Meeting)","fr":"MPSNDS (Réunion préalable – RPPDN)"},
  {"id":"B02-20160301-050","en":"NC (Notifiable Change)","fr":"NC (Préavis de modification)"},
  {"id":"B02-20160301-051","en":"NDS (New Drug Submission)","fr":"NDS (Présentation de drogue nouvelle)"},
  {"id":"B02-20160301-067","en":"PAND (Pandemic Application)","fr":"PAND (Demande pandémique)"},
  {"id":"B02-20160301-068","en":"PBR-C ","fr":"PBR-C "},
  {"id":"B02-20160301-069","en":"PBR-PV ","fr":"PBR-PV "},
  {"id":"B02-20160301-075","en":"PRNDS (Priority Request NDS)","fr":"PRNDS (Demande de statut d’évaluation prioritaire - PDN)"},
  {"id":"B02-20160301-077","en":"PRSNDS (Priority Request SNDS)","fr":"PRSNDS (Demande de statut d’évaluation prioritaire - SPDN)"},
  {"id":"B02-20160301-078","en":"PSUR-C (Periodic Safety Update Report - Conditional)","fr":"PSUR-C (Rapport périodique de pharmacovigilance - Conditionnel)"},
  {"id":"B02-20160301-079","en":"PSUR-PV (Periodic Safety Update Report - Pharmacovigilance)","fr":"PSUR-PV (Rapport périodique de pharmacovigilance - pharmacovigilance)"},
  {"id":"B02-20160301-080","en":"RMP-PV (Risk Management Plan - Pharmacovigilance)","fr":"RMP-PV (Plan de gestion des risques - Pharmacovigilance)"},
  {"id":"B02-20160301-082","en":"SANDS (Supplement to an Abbreviated New Drug Submission)","fr":"SANDS (Supplément à une présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-084","en":"SNDS (Supplement to a New Drug Submission)","fr":"SNDS (Supplément à une présentation de drogue nouvelle)"},
  {"id":"B02-20160301-085","en":"SNDS-C (Supplement to a New Drug Submission - Conditional)","fr":"SNDS-C (Supplément à 'une présentation de drogue nouvelle - Conditionnelle)"},
  {"id":"B02-20160301-087","en":"UD-PV (Undefined Data Pharmacovigilance)","fr":"UD-PV (Données non définies – Pharmacovigilance)"},
  {"id":"B02-20160301-088","en":"UDRA (Undefined Regulatory Activity)","fr":"UDRA (Activité réglementaire non définie)"},
  {"id":"B02-20160301-089","en":"YBPR (Yearly Biologic Product Report)","fr":"YBPR (Rapport annuel sur un produit biologique)"},
  {"id":"B02-20160301-090","en":"DIN","fr":"DIN"}
]